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ABSTRACT
Fanconi anemia (FA) is a rare disease characterized by congenital defects,
bone marrow failure, and atypically early-onset cancers. The FA proteins function
cooperatively to repair DNA interstrand crosslinks. A major step in the activation
of the pathway is the monoubiquitination of the FANCD2 and FANCI proteins, and
their recruitment to chromatin-associated nuclear foci. The regulation and function
of FANCD2 and FANCI, however, is poorly understood. In addition, how chromatin
state impacts pathway activation is also unknown. In this study, we have examined
the influence of chromatin state on the activation of the FA pathway. We describe
potent activation of FANCD2 and FANCI monoubiquitination and nuclear foci
formation following treatment of cells with the histone methyltransferase inhibitor
BRD4770. BRD4770-induced activation of the pathway does not occur via the direct
induction of DNA damage or via the inhibition of the G9a histone methyltransferase,
a mechanism previously proposed for this molecule. Instead, we show that BRD4770inducible FANCD2 and FANCI monoubiquitination and nuclear foci formation may
be a consequence of inhibition of the PRC2/EZH2 chromatin-modifying complex. In
addition, we show that inhibition of the class I and II histone deacetylases leads to
attenuated FANCD2 and FANCI monoubiquitination and nuclear foci formation. Our
studies establish that chromatin state is a major determinant of the activation of
the FA pathway and suggest an important role for the PRC2/EZH2 complex in the
regulation of this critical tumor suppressor pathway.

highly orchestrated DNA repair pathways to effectively
repair damaged DNA. Chromatin represents the
higher order macromolecular complex of DNA and
histone proteins, and chromatin plasticity has become
increasingly recognized as a major determinant of DNA
damage recognition, signaling, and repair [1–3]. The
nucleosome is the fundamental subunit of chromatin
and exhibits plasticity via compositional alteration,
translational repositioning, and the posttranslational
modification of histone tails. Histone tails are subject

INTRODUCTION
All organisms are continuously exposed to
endogenous and exogenous DNA damaging agents,
including reactive oxygen species and aldehydes from
normal metabolic processes and UV irradiation from
sunlight. The timely and accurate repair of DNA damage
is essential for the maintenance of genome stability and
organismal survival. As a consequence, prokaryotic
and eukaryotic organisms have evolved complex and
www.impactjournals.com/oncotarget
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to a wide variety of posttranslational modifications
including acetylation, methylation, phosphorylation,
and ubiquitination [4]. Histone acetylation homeostasis
is mediated by histone acetyltransferases (HATs), e.g.
TIP60/KAT5, and deacetylases (HDACs), e.g. HDAC1
and HDAC2. Underscoring the importance of histone
acetylation in DNA repair, key roles for TIP60/KAT5,
HDAC1, and HDAC2 in the maintenance of genome
stability have been established [5–7].
Fanconi anemia (FA) is a rare autosomal and
X-linked genetic disease characterized by congenital
defects, bone marrow failure, and increased cancer risk
in early adulthood [8]. FA is caused by mutation of any
one of 21 genes. The FA proteins function primarily in
the repair of DNA interstrand crosslinks (ICLs), lesions
that block the replication and transcription machineries,
which lead to structural and numerical chromosome
aberrations if repaired erroneously [8–11]. A central step
in the activation of the FA pathway is the site-specific
monoubiquitination of the FANCD2 and FANCI proteins
[12–14]. Monoubiquitinated FANCD2 and FANCI
localize to discrete sites within chromatin where they
are hypothesized to promote the recruitment of several
structure-specific endonucleases, including FAN1
(FANCD2-associated nuclease 1) and FANCQ/ERCC4
[15–18]. While FANCD2 and FANCI function primarily
within chromatin, the contribution of chromatin plasticity,
and specifically, the effects of changes in histone tail
posttranslational modifications, on their activation and
function have yet to be determined. Furthermore, while
chromatin remodeling at DNA double-strand breaks
(DSBs) has been extensively studied [1–3], very little
is known about the role of chromatin remodeling in the
context of ICL repair.
In this study we have examined the influence of
chromatin structure on the activation of the FA pathway.
Specifically, we have examined the effects of histone
methyltransferase (HMT), demethylase (HDM), and
deacetylase (HDAC) inhibitors on FANCD2 and FANCI
monoubiquitination and their assembly into discrete
nuclear foci. We describe potent activation of FANCD2
and FANCI monoubiquitination in chromatin, and
enhanced FANCD2 and FANCI nuclear foci formation,
following cellular exposure to the HMT inhibitor
BRD4770. BRD4770-induced activation of the pathway
does not appear to occur via the direct induction of DNA
damage per se, or via the inhibition of the G9a histone
methyltransferase, a mechanism previously proposed for
this molecule [19]. In contrast, our results suggest that
BRD4770-induced activation of the pathway may be a
consequence of inhibition of PRC2 (Polycomb Repressive
Complex 2) and, specifically, its catalytic HMT EZH2. In
addition, we demonstrate that inhibition of class I and II
HDACs with trichostatin A (TSA) and vorinostat (SAHA)
leads to attenuated ICL-inducible FANCD2 and FANCI
monoubiquitination and nuclear foci formation. Our
www.impactjournals.com/oncotarget

results establish that chromatin plasticity, and in particular
the posttranslational modification of histone tails, is
a critical determinant in the activation of the FA tumor
suppressor pathway.

RESULTS
Activation of FANCD2 and FANCI
monoubiquitination by the HMTi BRD4770
To explore the effects of global alterations in
histone methylation on the activation of the FA pathway,
we exposed the transformed osteosarcoma cell line
U2OS and the nontransformed telomerase (hTERT)immortalized line BJ-TERT to the HMT inhibitors (HMTi)
BRD4770 and BIX01294 and the HDM inhibitors (HDMi)
GSK-J1 and PBIT, and examined FANCD2 and FANCI
monoubiquitination. BRD4770 is a S-adenosylmethionine
(SAM) mimetic and competitive inhibitor of PRC2/
EZH2 and G9a [19–21]. BIX01294 is a non-SAM
mimetic selective inhibitor of G9a [21]. Treatment with
BRD4770 resulted in a marked increase in FANCD2
and FANCI monoubiquitination in both U2OS and BJTERT cells, even in the absence of the ICL-inducing
agent mitomycin C (MMC) (Figure 1A and 1B, lane 3).
Indeed, the ratio of FANCD2-Ub to FANCD2 (L:S ratio)
was higher in cells treated with BRD4770 alone than
in cells treated with MMC alone (Figure 1A and B,
compare lanes 2 and 3). BRD4770-induced activation
of FANCD2 monoubiquitination also occurred in a
concentration-dependent manner (Figure 1C). In contrast,
no major effects on levels of spontaneous or ICL-inducible
FANCD2/I monoubiquitination were observed for the
other inhibitors tested, other than a slight increase in the
FANCD2/I L:S ratios following treatment of BJ-TERT
cells with GSK-J1 (Figure 1B).

BRD4770 promotes FANCD2 chromatin
localization and nuclear foci formation
Next, we examined the effects of BRD4770
treatment on the localization of FANCD2 to chromatin
and its assembly into nuclear foci. Cells were incubated
in the absence or presence of BRD4770, both with and
without MMC, and whole-cell (W), soluble cytoplasmic
and nuclear (S), and chromatin-enriched (C) protein
lysates were prepared and analyzed by immunoblotting.
We observed greatly elevated levels of monoubiquitinated
FANCD2 and FANCI in the chromatin fraction of cells
treated with BRD4770 alone (Figure 2A, compare
lanes 3 and 9). In addition, using immunofluorescence
microscopy (IF), we analyzed FANCD2 nuclear foci
formation, an indicator of the localization of FANCD2 to
sites of damaged DNA in chromatin [12, 22], following
treatment with BRD4770 alone and following combined
treatment with BRD4770 and MMC. We observed a
76444
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BRD4770-inducible activation of the FA pathway
does not occur via direct induction of DNA
damage, increased expression of the FA core
complex, or changes in cell cycle progression

striking increase in the percentage of nuclei exhibiting
greater than 5 FANCD2 foci in both U2OS and BJTERT cells following BRD4770 treatment (Figure
2B and Supplementary Figure 1A and 1B). Levels of
FANCD2 nuclear foci formation in cells treated with
BRD4770 alone were comparable to that observed
following MMC treatment (Supplementary Figure 1A
and 1B). These results identify BRD4770 as a major
inducer of FANCD2 monoubiquitination and nuclear foci
formation and strongly suggest that changes in histone
methylation status are a critical determinant in the
activation of the FA pathway. Consistent with BRD4770
functioning via the modification of chromatin structure,
we observed a distinct change in the staining pattern of
the heterochromatin marker HP1ɑ following BRD4770
treatment (Supplementary Figure 1C).

One possible explanation for BRD4770-induced
activation of FANCD2 and FANCI monoubiquitination
and nuclear foci formation is that BRD4770 induces
DNA damage directly. To test this hypothesis, we
examined levels of the phosphorylated H2A variant
H2AX (γH2AX), a well-established biomarker of
DNA DSB formation [23], in cells treated with and
without BRD4770. No differences in the number of
nuclei exhibiting γH2AX foci were observed between
untreated cells and cells treated with BRD4770, both
in the absence or presence of MMC (Figure 3A and

Figure 1: The HMTi BRD4770 induces the monoubiquitination of FANCD2 and FANCI. (A) and (B), U2OS (A) and BJ-

TERT (B) cells were incubated in the absence (NT) or presence of 10 μM BRD4770, 2.5 μM BIX01294, 5 μM GSK-J1 and 1 μM PBIT,
with (+) and without (-) 200 nM mitomycin C (MMC) for 24 h. Whole-cell lysates were prepared and immunoblotted with anti-FANCD2,
anti-FANCI, and anti-ɑ-Tubulin antibodies. (C) U2OS cells were incubated with the indicated concentrations of BRD4770 and BIX01294
for 24 h, and whole-cell lysates were immunoblotted with anti-FANCD2, anti-FANCI, and anti-ɑ-Tubulin antibodies. L:S Ratio, ratio of
monoubiquitinated to nonubiquitinated FANCD2 or FANCI.
www.impactjournals.com/oncotarget
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Supplementary Figure 2). Similar results were observed
in both U2OS and BJ-TERT cells (Figure 3A and
Supplementary Figure 2). U2OS cells have a highly
unstable karyotype, with recurrent breakage-fusionbridge cycles most likely contributing to the elevated
spontaneous levels of γH2AX nuclear foci formation
observed in these cells (Supplementary Figure 2). While
we observed a faint γH2AX signal for cells treated with
BRD4770 alone via immunoblotting, this level was
markedly lower than that observed following exposure
to the topoisomerase type II inhibitor etoposide (VP-16),
a well known inducer of DNA DSBs, and no different to
that observed following GSK-J1 treatment (Figure 3B).
We also examined levels of RPA S4/8 phosphorylation,
a marker of single-stranded DNA [24], following
BRD4770 exposure. While MMC treatment led to a

strong increase in levels of RPA pS4/8, no increase in
levels above that of untreated cells was observed for
BRD4770 (Figure 3C). We also examined the effects of
BRD4770 treatment on levels of the FA core complex
proteins FANCA and UBE2T/FANCT. UBE2T/FANCT
is the FANCD2 E2 ubiquitin-conjugating enzyme [25].
Levels of both proteins decreased following BRD4770
treatment (Figure 3C). Decreased levels of FANCA were
also observed following exposure of HCT116 p53+/+ and
p53-/- cells to BRD4770 (see Supplementary Figure 3D).
Similarly, we observed a reduction in levels of the
USP1 de-ubiquitinating enzyme following BRD4770
treatment (Figure 3C). Concomitant reductions in the
levels of FANCA, UBE2T/FANCT, and USP1 cannot
explain the observed BRD4770-induced FANCD2 and
FANCI monoubiquitination and nuclear foci formation.

Figure 2: The HMTi BRD4770 induces FANCD2 chromatin localization and nuclear foci formation. (A) U2OS cells were

incubated in the absence (NT) or presence of 10 μM BRD4770 with (+) and without (-) 200 nM mitomycin C (MMC) for 24 h. Whole-cell
lysates (W) and soluble nuclear and cytoplasmic (S) and chromatin-enriched (C) fractions were prepared and immunoblotted with antiFANCD2, anti-FANCI, anti-H2A, and anti-ɑ-Tubulin antibodies. (B) U2OS cells were incubated with (+) and without (-) 200 nM MMC
in the absence (NT) or presence of 10 μM BRD4770 for 24 h. Cells were fixed and stained with rabbit polyclonal anti-FANCD2 antibody
(green) and counterstained with DAPI (blue), and the number of nuclei with >5 FANCD2 foci were scored. At least 300 nuclei were scored
for each treatment. Representative immunofluorescence microscopy images are shown.
www.impactjournals.com/oncotarget
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We observed an increase in levels of phosphorylated
CHK1 S345 following treatment with BRD4770,
albeit to a lesser extent than that observed following
MMC treatment (Figure 3C). Finally, we examined the
effects of BRD4770 treatment on cell cycle progression.
Following exposure to BRD4770 for 24 h, we observed
an increase in the percentage of cells in S-phase at all
concentrations of BRD4770 examined (Figure 3D).
However, following exposure to BRD4770 for 48 and

72 h, where maximal induction of FANCD2 and FANCI
monoubiquitination was observed (see Figure 4B), the
cell cycle stage profiles did not differ substantially from
that of untreated cells (Figure 3D). Taken together, these
results argue that BRD4770-induced activation of the FA
pathway does not appear to be a consequence of direct
induction of DNA damage, alterations in expression of
the FANCD2 core monoubiquitination proteins, or major
changes to cell cycle progression.

Figure 3: BRD4770-induced activation of the FA pathway does not occur via the direct induction of DNA damage
or altered cell cycle progression. (A) BJ-TERT cells were incubated with (+) and without (-) 200 nM mitomycin C (MMC) in

the absence (NT) or presence of 10 μM BRD4770 for 24 h. Cells were fixed and stained with mouse monoclonal anti-γH2AX antibody
and counterstained with DAPI, and the number of nuclei with >5 γH2AX foci were scored. At least 300 nuclei were scored for each
treatment and this experiment was performed three times with similar results. Error bars represent the standard errors of the means from
three independent experiments. (B) BJ-TERT cells were incubated with (+) and without (-) 0.4 μM etoposide (VP-16), in the absence or
presence of 10 μM BRD4770, 5 μM GSK-J1 and 2.5 μM BIX01294, for 24 h. Whole-cell lysates were immunoblotted with anti-γH2AX
and anti-PCNA (loading control) antibodies. (C) U2OS cells were incubated in the absence (NT) or presence of 200 nM MMC or 5 and 10
μM BRD4770 for 24 h. Whole-cell lysates were prepared and immunoblotted with anti-FANCD2, anti-FANCA, anti-UBE2T, anti-USP1,
anti-CHK1 pS345, anti-RPA, anti-RPA pS4/8, and anti-ɑ-Tubulin antibodies. L:S Ratio, ratio of monoubiquitinated to nonubiquitinated
FANCD2; RBI, relative band intensity. (D) U2OS cells were incubated in the absence or presence of 2, 5, and 10 μM BRD4770 for 24, 48,
or 72 h. Cells were fixed in ice-cold ethanol, stained with propidium iodide, and analyzed by flow cytometry. Cell cycle stage distributions
were determined using FlowJo v10.2.
www.impactjournals.com/oncotarget
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BRD4770-induced activation of the FA pathway
may occur via inhibition of the PRC2 complex

it exhibits specificity for G9a and PRC2 (Polycomb
Repressive Complex 2) [19]. EZH2 is the catalytic
HMT of PRC2, and catalyzes the deposition of the
transcriptionally repressive mark H3K27me3 [26].
Therefore, to determine if BRD4770-induced activation
of FANCD2 monoubiquitination might be a specific
consequence of G9a and/or EZH2 inhibition, we treated
cells with the DZNep and UNC0646 HMT inhibitors:
DZNep treatment has been reported to lead to cellular
depletion of EZH2 [27], while UNC0646 is a potent
inhibitor of G9a [28]. We observed modest induction
of FANCD2 and FANCI monoubiquitination following
exposure to 2 and 4 μM DZNep (Figure 4A). Considerable
cell toxicity was observed at 10 μM DZNep (results not
shown). Under these conditions, we did not observe a
decrease in levels of EZH2 expression. However, reduced

BRD4770 is a SAM mimetic and a structural
analogue of BIX01338, a non-selective HMT inhibitor
with similar IC50 values against the G9a and SUV39H1
HMTs [19–21]. Therefore, we next treated U2OS cells
with varying concentrations of BIX01338 to determine
if we would observe activation of the FA pathway,
similar to that observed for BRD4770. Surprisingly, we
did not observe any appreciable induction of FANCD2
or FANCI monoubiquitination following treatment with
BIX01338 for acute (24 h) (Supplementary Figure 3A)
or extended periods (up to 10 d) (results not shown).
BRD4770 is a methyl ester analogue of BRD9539, and
previous experiments with BRD9539 have shown that

Figure 4: BRD4770-induced activation of the FA pathway may occur via inhibition of the PRC2 complex. (A) U2OS cells

were incubated in the absence (NT) or presence of BRD4770, DZNep, UNC0646, and DZNep and UNC0646 combined (4 μM each) for 24
h. Whole-cell lysates were prepared and immunoblotted with anti-FANCD2, anti-FANCI, anti-EZH2, and anti-ɑ-Tubulin antibodies. (B)
U2OS cells were incubated in the absence or presence of 2, 5, and 10 μM BRD4770 for 24, 48, or 72 h. Whole-cell lysates were prepared
and immunoblotted with anti-FANCD2, anti-FANCI, anti-CHK1 pS345, anti-EZH2, anti-H3K27me3, and anti-ɑ-Tubulin antibodies. L:S
Ratio, ratio of monoubiquitinated to nonubiquitinated FANCI; or FANCD2 RBI, relative band intensity.
www.impactjournals.com/oncotarget

76448

Oncotarget

levels of EZH2 were observed following incubation with
DZNep, and BRD4770 to a lesser extent, for 4 and 8 days
(Supplementary Figure 3B). In contrast to DZNep, no
induction of FANCD2/I monoubiquitination was observed
following treatment with UNC0646, and combined
DZNep/UNC0646 treatment resulted in considerable cell
death (Figure 4A and results not shown). Consistent with
these findings, we also observed a modest yet statistically
significant increase in FANCD2 nuclear foci formation
in cells treated with DZNep and not with UNC0646
(Supplementary Figure 3C). We note that the degree of
DZNep-induced FANCD2/I monoubiquitination was
experimentally variable, most likely a consequence of its
pleiotropic nature. To further explore the potential role of
EZH2 and H3K27me3 in BRD4770-inducible FANCD2/I
monoubiquitination, we exposed U2OS cells to BRD4770
for 24, 48, and 72 h and examined levels of EZH2 and
H3K27me3 (Figure 4B). We observed reductions in
levels of H3K27me3 following treatment with higher
concentrations of BRD4770 for 72 h, when induction of
FANCD2 monoubiquitination was maximal (Figure 4B).
Under the same conditions, we did not observe any
significant reductions in EZH2 levels (Figure 4B).
Similarly, we also observed a modest reduction in levels of
H3K27me3 in HCT116 p53-/- cells treated with BRD4770
for 24 h and a more pronounced reduction in HeLa cells
treated with BRD4770 for 72 h (Supplementary Figures
3D and 3E). We again observed induction of CHK1 pS345
upon exposure to higher concentrations of BRD4770 for
extended periods (Figure 4B).

the PRC2 complex, and specifically EZH2 HMT activity,
and a consequent decrease in levels of H3K27me3.

Inhibition of class I and II HDACs attenuates
activation of the FA pathway
To investigate the influence of histone acetylation
state on the activation of the FA pathway, we next
examined the effects of the class I and II HDAC inhibitors
trichostatin A (TSA) and vorinostat (SAHA) on FANCD2
and FANCI monoubiquitination and nuclear foci
formation. Interestingly, for HeLa cells, we did not observe
any appreciable differences in the levels of spontaneous
or ICL-inducible FANCD2 or FANCI monoubiquitination
when cells were treated with TSA or SAHA (Figure 6A
and 6B). In contrast, when BJ-TERT cells were treated
with TSA or SAHA, we observed a marked reduction
in the levels of ICL-inducible FANCD2 and FANCI
monoubiquitination (Figure 6C and 6D). TSA and SAHA
treatment led to a reduction in ICL-inducible CHK1 S345
phosphorylation in both lines examined (Figure 6). In
contrast, incubation with TSA and SAHA did not lead to
any observable changes in levels of ICL-inducible CHK2
pT68 (Figure 6). We observed a concentration-dependent
increase in the levels of H4K16ac following treatment
with TSA and SAHA confirming their inhibition of histone
deacetylation (Figure 6). We also observed a reduction
in spontaneous and ICL-inducible FANCD2 nuclear
foci formation in both HeLa and BJ-TERT cells treated
with TSA or SAHA (Figure 7A–7D). Consistent with
our immunoblotting results, this effect was particularly
striking for BJ-TERT cells with a lesser effect observed
for HeLa cells (Figure 7A–7D).
The FA pathway is a major determinant of cellular
sensitivity to ICL-inducing agents. Therefore we next
examined if treatment with HDAC I and II inhibitors
would sensitize cells to the cytotoxic effects of MMC.
Indeed, even at the low concentrations of inhibitors
examined, treatment with the HDAC I and II inhibitors
sodium butyrate (NaB) and TSA sensitized BJ-TERT
cells to the cytotoxic effects of MMC over a range of
MMC concentrations (Figure 8A and 8B). In contrast,
treatment with nicotinamide (NAM), an inhibitor of the
NAD+ (nicotinamide adenine dinucleotide)-dependent
sirtuin (class III) family of HDACs, did not impact
cellular sensitivity to MMC (Figure 8C). Taken together,
our results indicate that HDAC1 and HDAC2 positively
regulate activation of the FA pathway and that cellular
sensitivity to ICL-inducing agents, which are widely used
in cancer chemotherapy, may be increased via HDAC1/2
inhibition.

EPZ-6438-mediated inhibition of PRC2/
EZH2 leads to activation of FANCD2
monoubiquitination
To further analyze the role of PRC2 and EZH2 in
the activation of the FA pathway, cells were treated with
EPZ-6438, an EZH2-specific inhibitor [29, 30], and
FANCD2 and FANCI monoubiquitination and nuclear
foci formation were analyzed. In MCF10A cells, a
spontaneously-immortalized, nontransformed, mammary
epithelial line, EPZ-6438 treatment led to a pronounced
increase in FANCD2 and FANCI protein levels, FANCD2
and FANCI monoubiquitination, and FANCD2 nuclear
foci formation (Figure 5A and Supplementary Figure 4).
Interestingly, EPZ-6438 treatment led to an increase in
levels of EZH2, possibly a cellular response to chemical
inhibition of EZH2, and an overall reduction in levels of
H3K27me3 (Figure 5A). EPZ-6438 treatment also resulted
in increased FANCD2 monoubiquitination in isogenic
HCT116 p53+/+ and p53-/- cells (Figure 5B) and HeLa cells
(Figure 5C). In contrast to MCF10A, HeLa, and HCT116,
we did not detect increased FANCD2 monoubiquitination
in U2OS cells treated with EPZ-6438 (results not shown).
Taken together, our results suggest that BRD4770-induced
activation of the FA pathway may occur via inhibition of
www.impactjournals.com/oncotarget

DISCUSSION
In this study, we have established that chromatin
state is an important determinant in the activation of
76449
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primarily via the inhibition of G9a [19]. However, in
our experiments, while BRD4770 robustly promoted
FA pathway activation, several G9a-specific inhibitors including BIX01294 and UNC0646 - failed to promote
FA pathway activation. Our results suggest that BRD4770
does not act primarily via G9a inhibition, and that G9a
does not play a significant role in the regulation of the FA
pathway. Instead, our findings suggest that BRD4770 may
exert its cellular effects, at least in part, via the inhibition

the FA pathway. Specifically, we have established that
treatment with the HMTi BRD4770 and inhibition of the
class I and II HDACs strongly impacts activation of the FA
pathway. BRD4770 was recently discovered in a focused
screen of a 2-substituted benzimidazole library [19]. While
in in vitro biochemical assays, BRD9539, the carboxylic
acid derivative of BRD4770, effectively inhibited both
G9a and PRC2/EZH2 in a concentration-dependent
manner, these studies concluded that BRD4770 functions

Figure 5: Activation of FANCD2 monoubiquitination following treatment with the EZH2 inhibitor EPZ-6438. (A-C)

MCF10A (A), HCT116 p53+/+ and p53-/- (B), and U2OS (C) cells were treated with the indicated concentrations of the EZH2-specific
inhibitor EPZ-6438 for 24 h (A and B) or 24, 48, and 72 h (C). Whole-cell lysates were prepared and immunoblotted with the indicated
antibodies. L.E., light exposure; D.E., dark exposure; L:S Ratio, ratio of monoubiquitinated to nonubiquitinated FANCI; or FANCD2 RBI,
relative band intensity.
www.impactjournals.com/oncotarget
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of PRC2/EZH2, and that PRC2/EZH2 may play an
important role in the regulation of the activation of the FA
pathway. Several findings support this model: Exposure
to BRD4770 resulted in reduced levels of H3K27me3 the transcriptionally repressive mark deposited by PRC2/
EZH2 [26] - in several cell models. Modest activation of
FANCD2 monoubiquitination and nuclear foci formation
was observed following treatment with the PRC2/EZH2
inhibitor DZNep [27]. However, while DZNep was
initially reported to be selective for PRC2/EZH2 [27], as a
S-adenosylhomocysteine hydrolase inhibitor, DZNep can
also affect global histone methylation patterns [31]. This
led us to examine the effects of inhibition of EZH2 with
the SAM-competitive inhibitor EPZ-6438. EPZ-6438 is
a potent and selective EZH2 inhibitor with an inhibition
constant (Ki) of 2.5 nM. EPZ-6438 is 35-fold and >4,500fold more selective for EZH2 than EZH1 and 14 other
HMTs examined [32]. In four out of five lines examined

in this study, EPZ-6438 treatment led to an increase in
levels of FANCD2 monoubiquitination. The mechanism(s)
by which inhibition of PRC2/EZH2 and decreased global
levels of H3K27me3 would lead to activation of the FA
pathway remain to be clearly elucidated. Recent studies
in the silkworm Bombyx mori have shown that PRC2mediated H3K27me3 increases following exposure to UV
irradiation [33]. One possibility is that, upon exposure
to DNA damaging agents, transcription may need to be
halted at loci that have incurred DNA damage. An inability
to catalyze H3K27me3 and arrest transcription could
lead to the formation of co-transcriptional RNA-DNA
hybrids (R-loops). An important role for the FA proteins
in the repair of R-loops has recently been established
[34, 35]. However, our γH2AX and RPA pS4/8 results
strongly suggest a DNA damage-independent mode of
action for BRD4770. An alternative hypothesis is that
BRD4770 treatment - possibly via both G9a and PRC2/

Figure 6: Inhibition of class I and II HDACs attenuates FANCD2 and FANCI monoubiquitination in BJ-TERT cells.

(A) and (B), HeLa cells were pre-treated with the indicated concentrations of trichostatin A (TSA) (A) or vorinostat (SAHA) (B) for 4 h,
followed by co-incubation with (+) and without (-) 200 nM MMC for a further 20 h. Whole-cell lysates were prepared and immunoblotted
with anti-FANCD2, anti-FANCI, anti-CHK1 pS345, anti-CHK2 pT68, anti-H4K16ac, and anti-ɑ-Tubulin antibodies. (C) and (D), BJTERT cells were treated identically to that described for HeLa cells above. L:S Ratio, ratio of monoubiquitinated to nonubiquitinated
FANCD2 or FANCI.
www.impactjournals.com/oncotarget

76451

Oncotarget

EZH2 inhibition - leads to the general establishment of a
transcriptionally permissive chromatin state, which leads
to the recruitment of factors that promote homologous
recombination (HR) DNA repair, such as FANCD2

and FANCI [13, 36]. Consistent with this hypothesis,
Aymard et al have recently shown that HR factors are
enriched at transcriptionally active chromatin [37]. It
is important to note, however, that BRD4770-induced

Figure 7: Inhibition of class I and II HDACs attenuates FANCD2 nuclear foci formation. (A) and (B), HeLa cells were

treated with the indicated concentrations of trichostatin A (TSA) (A) or vorinostat (SAHA) (B) in the absence (NT) or presence (MMC)
of 200 nM mitomycin C (MMC) for 24 h. Cells were fixed and stained with rabbit polyclonal anti-FANCD2 antibody and counterstained
with DAPI, and the number of nuclei with >5 FANCD2 foci were scored. *, P < 0.05; **, P < 0.01; ***, P < 0.001, with comparison to
untreated cells. (C) and (D), BJ-TERT cells were treated identically to that described for HeLa cells above. At least 300 nuclei were scored
for each treatment and these experiments were performed three times with similar results. Error bars represent the standard errors of the
means from three independent experiments.

Figure 8: Inhibition of class I and II HDACs sensitizes cells to the cytotoxic effects of mitomycin C. BJ-TERT cells were
exposed to the indicated concentrations of mitomycin C (MMC) in the absence or presence of (A) 5 mM sodium butyrate (NaB), (B) 331
nM trichostatin A (TSA), or (C) 10 mM nicotinamide (NAM) and cellular proliferation was determined using the CellTiter 96® AQueous
One Solution Cell Proliferation (MTS) assay. Error bars represent the standard errors of the means from three independent experiments.
www.impactjournals.com/oncotarget
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activation of the FA pathway most likely does not occur
solely via the inhibition of PRC2/EZH2: BRD4770
induces FANCD2/I monoubiquitination more robustly
than the EZH2-specific inhibitor EPZ-6438, and EPZ6438 treatment results in more pronounced decreases in
levels of H3K27me3. Therefore, other mechanisms are
likely to contribute to the observed effects of BRD4770.
In our study, we also detected increased phosphorylation
of CHK1 S345 following BRD4770 exposure, indicating
activation of the ATR-CHK1 checkpoint-signaling
pathway. Numerous studies have indicated an important
role for this pathway in signaling aberrant changes in
chromatin structure [38–40]. One possibility is that
BRD4770-induced changes in chromatin state lead
to activation of ATR, phosphorylation of CHK1 and
monoubiquitination of FANCD2, leading to activation
of the intra-S-phase checkpoint. These findings are
consistent with a large body of evidence linking the
ATR-CHK1 signaling pathway to the activation of the FA
pathway [41–44]. However, while BRD4770 treatment
for 24 h did lead to an accumulation of cells in S-phase,
exposure to BRD4770 for longer periods - when levels
of phosphorylated CHK1 S345 and monoubiquitinated
FANCD2 were maximal - did not appear to result in
an overt S-phase arrest. Further experiments will be
required to determine the relationship between changes in
chromatin state, activation of the ATR-CHK1-FANCD2
axis and maintenance of the intra-S-phase checkpoint.
Here, we have also established that chemical
inhibition of class I and II HDACs leads to attenuation
of FANCD2 and FANCI monoubiquitination in BJTERT cells, with a less pronounced effect in HeLa cells,
and significant reductions in FANCD2 nuclear foci
formation in both HeLa and BJ-TERT cells. FANCD2/I
monoubiquitination and nuclear foci are not strictly
coupled: Usp1-/- murine cells exhibit increased Fancd2
monoubiquitination in the absence of nuclear foci
formation [45]. Thus, under the conditions examined,
our findings point to an important role for histone
deacetylation in facilitating the efficient activation of
the FA pathway. Previous studies in the budding yeast
S. cerevisiae, have shown that valproic acid (VPA),
a class I and II HDACi, inhibits Mec1 (orthologue of
human ATR) signaling [46]. This is consistent with
our observation of reduced ICL-inducible CHK1 S345
phosphorylation following HDAC inhibition with SAHA
and TSA. Taken together with our BRD4770 findings, our
results indicate that the ATR-CHK1 signaling pathway
responds to changes in chromatin structure, and that
phosphorylation and activation of CHK1 correlates with
monoubiquitination and activation of FANCD2.
Several studies have established that, during the
very early stages of DSB repair - seconds to minutes a transient repressive chromatin state is first established,
characterized by the spreading of HP1 and H3K9me2/3
[47]. The multisubunit NuRD repressor complex is rapidly
www.impactjournals.com/oncotarget

recruited to sites of DNA damage where it promotes
histone deacetylation and chromatin remodeling [48–50].
This may be necessary to restrict transcription in the
immediate vicinity of the damaged site and to promote
the recruitment of repair factors [47]. A failure to rapidly
establish this transient repressive chromatin state would
be predicted to lead to inefficient activation of DNA repair
pathways, as we have observed following ICL treatment
and HDAC inhibition. In contrast, a failure to catalyze
H3K27me3 upon exposure to BRD4770 or EPZ-6438 may
lead to persistent, constitutively open/relaxed chromatin,
which in turn may promote the inadvertent activation of
repair mechanisms, as previously shown [51].
In summary, our results establish that chromatin
state is an important determinant of the activation of the
FA pathway. Our findings also suggest that combination
chemotherapy comprising ICL-inducing agents and
HDAC inhibitors may be an effective strategy for
certain cancers. Recent studies have identified three
functional modules within the FA core complex: the
FANCB-FANCL-FAAP100 module, which provides the
essential monoubiquitination catalytic activity, and the
FANCA-FANCG-FAAP20 and FANCC-FANCE-FANCF
modules, which are thought to promote the recruitment of
the core complex to chromatin [52, 53]. The majority of
FA patients harbor mutations in the FANCA and FANCG
genes, and FANCD2/I monoubiquitination is defective
in >95% of FA patients [54]. Based on our findings,
it is conceivable that the chromatin recruitment of the
monoubiquitination catalytic module could be promoted
via chemical modification of chromatin state, raising the
prospect of epigenetics-based therapeutic approaches for
certain FA complementation groups.

MATERIALS AND METHODS
Cell culture
The osteosarcoma cell line U2OS, the cervical
carcinoma cell line HeLa, and the hTERT-immortalized
BJ-TERT cells were grown in DMEM supplemented with
15% v/v fetal bovine serum, 2 mM L-glutamine, 50 U/mL
penicillin, and 50 μg/mL streptomycin. HCT116 p53+/+ and
p53-/- cells were grown in McCoy’s 5A medium containing
the same supplements [55]. MCF10A mammary epithelial
cells were grown in DMEM F12 supplemented with
5% v/v horse serum, 20 ng/ml epidermal growth factor,
0.5 mg/ml hydrocortisone, 100 ng/ml cholera toxin, 10 μg/
ml insulin, 2 mM L-glutamine, 50 U/mL penicillin, and 50
μg/mL streptomycin.

Chemicals
The structures of all chemicals used in this study are
shown in Supplementary Figure 5. The following chemicals
were used: BRD4770 (histone methyltransferase inhibitor
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VI) (C25H23N3O3) (382194; EMD Millipore), BIX01294
(C28H38N6O2.3HCl.xH2O) (B9311; Sigma), GSK-J1 (histone
lysine demethylase inhibitor VII) (C22H23N5O2) (420204;
EMD Millipore), PBIT (histone lysine demethylase inhibitor
IX) (C14H11NOS) (505299; EMD Millipore), UNC0646
(C36H59N7O2) (SML0633; Sigma), BIX01338 (C32H24F3N
O .xH2O) (B5313; Sigma), DZNep (3-Deazaneplanocin
3 6
A) (C12H14N4O3) (13828; Cayman Chemical), EPZ-6438
(Tazemetostat) (C34H44N4O4) (S7128; Selleckchem), SAHA
(Vorinostat) (C14H20N2O3) (SML0061; Sigma), Trichostatin
A (TSA) (C17H22N2O3) (T1952; Sigma), Mitomycin C
(MMC) (C15H18N4O5) (BP25312; Fisher Scientific), and
Etoposide (VP-16) (C29H32O13) (E1383; Sigma).

with AxioVision LE 4.6 image acquisition software.
Primary antibodies used for IF were anti-FANCD2
(NB100-182; Novus Biologicals), anti-FANCI (A300212A; Bethyl Laboratories), and anti-γH2AX (05-636;
Millipore). Statistical significance was determined using
paired two-tailed Student’s t-test analysis.

Chromatin fractionation
Cells were plated at density of 3 x 106 cells in 15 cm2
dishes. The following day, cells were treated with 200 nM
MMC for 24 h. Cells were harvested and resuspended in
ice-cold PBS. A portion of the pellet was retained as a
whole cell lysate (W). The remaining pellet was lysed on
ice in cytoskeletal buffer (CSK) (300 mM Sucrose, 100
mM NaCl, 3 mM MgCl2, 0.5% v/v Triton-X-100, 1 mM
EGTA, 10 mM PIPES, pH 6.8). The supernatant, containing
soluble cytoplasmic and nuclear proteins, was collected as
the soluble fraction (S). The remaining pellet, containing
chromatin-associated and nuclear insoluble proteins (C),
and the whole-cell lysate pellet, were lysed in 2% SDS lysis
buffer with sonication for 10 s at 10% amplitude using a
Fisher Scientific Model 500 Ultrasonic Dismembrator.

Immunoblotting and antibodies
For immunoblotting analysis, cell pellets were washed
in PBS and lysed in 2% w/v SDS, 50 mM Tris-HCl, 10 mM
EDTA. Proteins were resolved on NuPage 3-8% w/v TrisAcetate or 4-12% w/v Bis-Tris gels (Invitrogen) and
transferred to polyvinylidene difluoride (PVDF) membranes.
The following antibodies were used: mouse monoclonal sera
against γH2AX (05-636; Millipore), HDAC1 (5356; Cell
Signaling), HDAC2 (5113; Cell Signaling), HP1α (05-689;
Millipore), PCNA (sc-56; Santa Cruz Biotechnology),
RPA (NA18; Calbiochem), and α-tubulin (MS-581-PO;
Neomarkers), rabbit monoclonal serum against CHK1
pS345 (2348; Cell Signaling), and rabbit polyclonal sera
against CHK2 pT68 (2661; Cell Signaling), EZH2 (5246S;
Cell Signaling), FANCA (ABP6201; Cascade), FANCD2
(NB100-182; Novus Biologicals), FANCI (A301-254A;
Bethyl Laboratories), H2A (07-146; Millipore), H3K27me3
(9733P; Cell Signaling), H4K16ac (07-329; Millipore), RPA
pS4/8 (A300-245A; Bethyl), USP1 (a kind gift from Tony
T. Huang, New York University), and UBE2T (A301-874A;
Bethyl).

Cell proliferation assay
Cells were plated at a density of 10,000 cells/well
in 96-well dishes, incubated in the absence or presence of
drug(s) for 48 h. CellTiter 96® AQueous One Solution Reagent
(MTS) (Promega) was added directly to the wells, incubated
for a further 2 h, and the absorbance at 490 nm was measured
using a 96-well Bio-Rad 680 microplate reader.

Cell-cycle analysis
Cells were plated at a density of 1x106 cells in 10 cm2
dishes. The following day, cells were incubated in the absence
or presence of 2, 5, and 10 μM BRD4770 for 24, 48, and 72
h. Cells were resuspended in 0.1 mL PBS and fixed by adding
1 mL ice-cold methanol. Cells were washed in PBS and
incubated in 50 μg/mL propidium iodide (PI) (Sigma) and
30 U/mL RNase A for 10 min at 37°C, followed by analysis
using a BD FACSVerse flow cytometer. The percentages of
cells in G1, S, and G2/M were determined by analyzing PI
histograms with FlowJo V10.2 software.

Immunofluorescence microscopy
For immunofluorescence microscopy (IF) analysis,
cells were seeded in 4-well tissue culture slides (BD
Falcon) in the presence or absence of drug(s) for 24 h.
Soluble cellular proteins were pre-permeabilized with
0.3% v/v Triton X-100 and cells were fixed in 4% w/v
paraformaldehyde and 2% w/v sucrose at 4°C followed by
permeabilization in 0.3% v/v Triton X-100 in PBS. Fixed
cells were blocked for 30 minutes in antibody dilution
buffer (5% v/v goat serum, 0.1% v/v NP-40, in PBS)
and incubated with primary antibody for 1 h. Cells were
washed three times in PBS, as well as permeabilization
buffer, and incubated for 30 min at room temperature with
an Alexa Fluor 488-conjugated secondary antibody and the
slides were counterstained and mounted in vectashield plus
4’6-diamidine-2-phenylindole dihydrochloride (DAPI)
(Vector Laboratories). Nuclear foci were scored using a
Zeiss AxioImager.A1 upright epifluorescence microscope
www.impactjournals.com/oncotarget
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